UB401
TargetsUSP1
IndicationsSolid tumour
ClinicalCN - IND
TherapeuticsOncology
ModalitiesSmall Molecule
Exclusive Summary
- No significant inhibition of the CYP metabolic pathway, making it favorable for combination therapy.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →